EICHORPublic-registry site landscape for NCT03616470, “Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia”, a Acute Myeloid Leukemia study sponsored by GlycoMimetics Incorporated. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03616470 (registry record) |
| Study title | Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia |
| Official title | A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia |
| Sponsor | GlycoMimetics Incorporated |
| Condition(s) | Acute Myeloid Leukemia |
| Phase | PHASE3 |
| Listed sites | 70 |
| Site countries | United States, Australia, Canada, France, Ireland, Italy, Netherlands, Spain, United Kingdom |
Patient-friendly overview of this study: eichor.com/study/NCT03616470.
Eichor generates a preliminary site-risk snapshot for NCT03616470 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Acute Myeloid Leukemia trials
← Eichor home · All tracked trials · Acute Myeloid Leukemia studies · Weekly briefs
